Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Waning of SARS-CoV-2 booster viral-load reduction effectiveness

View ORCID ProfileMatan Levine-Tiefenbrun, View ORCID ProfileIdan Yelin, Hillel Alapi, Esma Herzel, Jacob Kuint, Gabriel Chodick, View ORCID ProfileSivan Gazit, Tal Patalon, View ORCID ProfileRoy Kishony
doi: https://doi.org/10.1101/2021.12.27.21268424
Matan Levine-Tiefenbrun
1Faculty of Biology, Technion - Israel Institute of Technology, Haifa, Israel
2Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matan Levine-Tiefenbrun
Idan Yelin
1Faculty of Biology, Technion - Israel Institute of Technology, Haifa, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Idan Yelin
Hillel Alapi
3Maccabitech, Maccabi Health Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esma Herzel
3Maccabitech, Maccabi Health Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacob Kuint
2Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
3Maccabitech, Maccabi Health Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriel Chodick
2Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
3Maccabitech, Maccabi Health Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sivan Gazit
3Maccabitech, Maccabi Health Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sivan Gazit
Tal Patalon
3Maccabitech, Maccabi Health Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: patalon_t@mac.org.il rkishony@technion.ac.il
Roy Kishony
1Faculty of Biology, Technion - Israel Institute of Technology, Haifa, Israel
4Faculty of Computer Science, Technion - Israel Institute of Technology, Haifa, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Roy Kishony
  • For correspondence: patalon_t@mac.org.il rkishony@technion.ac.il
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The BNT162b2 COVID-19 vaccine has been shown to reduce viral load of breakthrough infections (BTIs), an important factor affecting infectiousness. This viral-load protective effect has been waning with time post the second vaccine and later restored with a booster shot. It is currently unclear though for how long this regained effectiveness lasts. Analyzing Ct values of SARS-CoV-2 qRT-PCR tests of over 22,000 infections during a Delta-variant-dominant period in Israel, we found that this viral-load reduction effectiveness significantly declines within months post the booster dose. Adjusting for age, sex and calendric date, Ct values of RdRp gene initially increased by 2.7 [CI: 2.3-3.0] relative to unvaccinated in the first month post the booster dose, yet then decayed to a difference of 1.3 [CI: 0.7-1.9] in the second month and became small and insignificant in the third to fourth months. The rate and magnitude of this post-booster decline in viral-load reduction effectiveness mirror those observed post the second vaccine. These results suggest rapid waning of the booster’s effectiveness in reducing infectiousness, possibly affecting community-level spread of the virus.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the Israel Science Foundation KillCorona-Curbing Coronavirus Research Program (grant no. 3633/19 to R. K. and G.C.) and a fellowship from the Edmond J. Safra Center for Bioinformatics at Tel-Aviv University (to M. L-T). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the MHS (Maccabi Healthcare Services) Institutional Review Board (IRB). Due to the retrospective design of the study, informed consent was waived by the IRB, and all identifying details of the participants were removed before computational analysis.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

According to Israel Ministry of Health regulations, individual-level data cannot be shared openly. Specific requests for remote access to de-identified data should be referred to KSM, the Maccabi Healthcare Services Research and Innovation Center. Requests sent to Sarit Chehanowitz (chehanow_s@mac.org.il) will be considered within 21 d pending IRB approval and Maccabi Healthcare Services regulations.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted December 29, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Waning of SARS-CoV-2 booster viral-load reduction effectiveness
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Waning of SARS-CoV-2 booster viral-load reduction effectiveness
Matan Levine-Tiefenbrun, Idan Yelin, Hillel Alapi, Esma Herzel, Jacob Kuint, Gabriel Chodick, Sivan Gazit, Tal Patalon, Roy Kishony
medRxiv 2021.12.27.21268424; doi: https://doi.org/10.1101/2021.12.27.21268424
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Waning of SARS-CoV-2 booster viral-load reduction effectiveness
Matan Levine-Tiefenbrun, Idan Yelin, Hillel Alapi, Esma Herzel, Jacob Kuint, Gabriel Chodick, Sivan Gazit, Tal Patalon, Roy Kishony
medRxiv 2021.12.27.21268424; doi: https://doi.org/10.1101/2021.12.27.21268424

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (557)
  • Anesthesia (135)
  • Cardiovascular Medicine (1769)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10812)
  • Forensic Medicine (8)
  • Gastroenterology (594)
  • Genetic and Genomic Medicine (2960)
  • Geriatric Medicine (288)
  • Health Economics (534)
  • Health Informatics (1933)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (293)
  • HIV/AIDS (633)
  • Infectious Diseases (except HIV/AIDS) (12525)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (87)
  • Nephrology (324)
  • Neurology (2808)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1473)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (868)
  • Pharmacology and Therapeutics (367)
  • Primary Care Research (338)
  • Psychiatry and Clinical Psychology (2646)
  • Public and Global Health (5383)
  • Radiology and Imaging (1016)
  • Rehabilitation Medicine and Physical Therapy (597)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (290)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (126)